Novo Nordisk A/S (NVO)
NYSE: NVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NVO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $168.89B
- P/E (TTM)
- 9.35
- Forward P/E
- 11.50
- EPS (TTM)
- $4.09
- Dividend yield
- 30.58% ($11.70)
- Ex-dividend date
- Aug 17, 2026
- 52-week range
- 35.12 – 64.16
- Day range
- 37.51 – 38.46
- Volume / Avg
- 13.53M / 12.52M
- Beta
- —
- Shares outstanding
- 3.34B
- Next earnings
- Nov 4, 2026
52-week range
NVO stock today
Shares of Novo Nordisk A/S (NVO) finished higher on Oct 7 at $38.26, a gain of 1.95% or $0.73 per share, versus the S&P 500's 0.22% decline. Shares are 40.4% below their 52-week high of $64.16, set on Jan 23, 2026 and 8.9% above the 52-week low of $35.12, near the bottom of the past year's range. NVO is down 24.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 35.2%.
At 9.4x trailing earnings, Novo Nordisk A/S trades below the peer-group median of 22.6x. Its forward P/E of 11.5x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. Novo Nordisk A/S's next earnings report is expected on Nov 4, 2026. Novo Nordisk A/S pays an annual dividend of $11.70 per share, a 30.58% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Novo Nordisk A/S
Company profileNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Maziar Mike Doustdar B.A.
- Headquarters
- Bagsvaerd
- Employees
- 66,700
- Website
- novonordisk.com
Analyst forecast
ForecastConsensus (14 analysts)
hold
Avg. price target
$46.07+20.41%
- Strong buy 0
- Buy 3
- Hold 10
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.80
Dividends
Dividend history- Annual dividend
- $11.70
- Dividend yield
- 30.58%
- Last payment
- $0.579
- Ex-dividend date
- Aug 17, 2026
NVO news
All NVO news- Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to KnowNasdaq
- Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond ZepboundNasdaqLLY, NVO, AMGN
- Pharma lobby group sues Trump administration over MFN pricingSeeking Alpha
- VKTX Advances Obesity Program With New Oral Maintenance StudyNasdaqVKTX, NVO, LLY
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?NasdaqNVO, LLY, ALT, MDGL
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?NasdaqNVO, LLY
- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowNasdaqAGIO, NVO, ALDX, ACIU
- Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?NasdaqLLY, NVO
Novo Nordisk A/S peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABTAbbott Laboratories | 98.73 | +0.58% | $170.84B | vs NVO |
| VRTXVertex Pharmaceuticals Incorporated | 505.64 | +0.66% | $128.16B | vs NVO |
| BMYBristol-Myers Squibb Company | 59.70 | +0.18% | $121.95B | vs NVO |
| SNYSanofi ADS | 40.20 | +1.62% | $96.32B | vs NVO |
| AZNAstraZeneca PLC | 160.12 | +0.95% | $248.33B | vs NVO |
| REGNRegeneron Pharmaceuticals Inc. | 742.12 | +0.46% | $76.40B | vs NVO |
| NVSNovartis AG | 143.28 | +1.77% | $272.33B | vs NVO |
| ONCBeOne Medicines Ltd. ADR | 364.02 | +0.34% | $41.41B | vs NVO |
Indexes, lists and sector
Appears in lists
Novo Nordisk A/S stock FAQ
What is Novo Nordisk A/S's stock price today?
NVO last traded at $38.26 as of Oct 7, 4:00 PM EDT, up 1.95% on the day. Prices are delayed at least 15 minutes.
Does Novo Nordisk A/S pay a dividend?
Yes. Novo Nordisk A/S pays $11.70 per share annually, a 30.58% yield. The most recent dividend of $0.579 had an ex-dividend date of Aug 17, 2026.
When is Novo Nordisk A/S's next earnings date?
Novo Nordisk A/S is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.80.
What is NVO's P/E ratio?
NVO trades at a trailing P/E ratio of 9.35 and a forward P/E of 11.50, compared with a median of 22.6 for its closest peers.
Who is Novo Nordisk A/S's CEO?
Mr. Maziar Mike Doustdar B.A. is the chief executive officer of Novo Nordisk A/S, which has about 66,700 employees.
Has NVO ever split its stock?
Yes. The most recent NVO stock split was a 2-for-1 split on Sep 20, 2023, one of 5 splits on record.
What is the NVO 52-week high?
The 52-week high for NVO is $64.16 and the 52-week low is $35.12. The stock is currently 40.4% below its high.